Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to
standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction
followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free
survival.